Lusis Eriks A, Chicoine Michael R, Perry Arie
Division of Neuropathology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Ave, St. Louis, MO 63110, USA.
J Neurooncol. 2005 Jul;73(3):219-23. doi: 10.1007/s11060-004-5233-y.
Meningiomas are histologically and clinically diverse CNS neoplasms with few available immunohistochemical markers of differentiation and progression. Therefore, we investigated a panel of potentially useful meningioma-associated biomarkers using high throughput tissue microarray immunohistochemistry (TMA-IHC) with a TMA that includes 9 hemangiopericytomas (HPCs) and 41 meningiomas spanning all grades, as well as two subsets of atypical meningiomas, stratified according to clinical behavior. Antibodies utilized were progesterone receptor (PR), epithelial membrane antigen (EMA), cathepsin D, E-cadherin, platelet derived growth factor (PDGF) receptor beta, PDGF BB ligand, survivin, epithelial growth factor receptor (EGFR), and vascular endothelial growth factor (VEGF). In most cases, frequencies of tumor positivity were similar to those previously reported using whole section IHC. EMA, E-cadherin, and PDGFR-beta staining patterns distinguished the anaplastic meningiomas from the HPCs (P < 0.001, P = 0.02, P = 0.015, respectively). As in prior studies, PR and cathepsin D expression were inversely proportional to tumor grade. However, PR and EGFR were also differentially expressed between symptomatic, surgically resected benign meningiomas and incidental meningiomas found at autopsy. We conclude that (1) TMA-IHC is an accurate and efficient way to rapidly assess biomarkers in meningeal tumors, (2) EMA, E-cadherin, and PDGFR-beta are useful in distinguishing anaplastic meningiomas from HPCs, and (3) the expression patterns for incidental meningiomas differ slightly from their surgically resected symptomatic counterparts.
脑膜瘤是组织学和临床上具有多样性的中枢神经系统肿瘤，几乎没有可用的免疫组化分化和进展标志物。因此，我们使用高通量组织微阵列免疫组化（TMA-IHC），对一组可能有用的脑膜瘤相关生物标志物进行了研究，该TMA包含9例血管外皮细胞瘤（HPC）和41例涵盖所有级别的脑膜瘤，以及根据临床行为分层的两个非典型脑膜瘤亚组。所使用的抗体包括孕激素受体（PR）、上皮膜抗原（EMA）、组织蛋白酶D、E-钙黏蛋白、血小板衍生生长因子（PDGF）受体β、PDGF BB配体、生存素、上皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）。在大多数情况下，肿瘤阳性频率与先前使用全切片免疫组化报告的频率相似。EMA、E-钙黏蛋白和PDGFR-β染色模式可将间变性脑膜瘤与HPC区分开来（分别为P < 0.001、P = 0.02、P = 0.015）。与先前的研究一样，PR和组织蛋白酶D的表达与肿瘤级别呈负相关。然而，PR和EGFR在有症状的手术切除的良性脑膜瘤和尸检时发现的偶然脑膜瘤之间也存在差异表达。我们得出结论：（1）TMA-IHC是快速评估脑膜肿瘤生物标志物的准确且有效的方法；（2）EMA、E-钙黏蛋白和PDGFR-β有助于区分间变性脑膜瘤与HPC；（3）偶然脑膜瘤的表达模式与其手术切除的有症状对应物略有不同。
